Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCAT 2023 | Genetic variants in SCD

Miguel Brito • 27 Oct 2023
ASCAT 2023
Non-Malignant Sickle Cell Disease

In this video, Miguel Brito, PhD, Lisbon School of Health Technology, Lisbon, Portugal, outlines the need to study genetic variants of sickle cell disease (SCD) in order to determine how they modulate the outcome of the disease. In future, genetic analysis of patients will allow clinicians to determine those most at risk of severe disease so that additional support can be provided to these individuals. This interview was recorded at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023, held in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Miguel Brito

2:00
The current landscape of SCD treatment
Miguel Brito • 27 Oct 2023
2:47
Genetic modifiers affecting the response to hydroxyurea in children with sickle cell anemia
Miguel Brito • 27 Oct 2023

Related Videos

2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals